4BIO Capital Portfolio Company Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus (EBV) driven disease

SparingVision named a ‘Fierce 15’ Company by Fierce Biotech

4BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing

4BIO Capital Participates in $130M Funding of New Gene and Cell Manufacturing Specialist Ascend

4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A

SparingVision’s lead asset SPVN06 clears IND application in the US for retinitis pigmentosa